CytomX Therapeutics, Inc. (CTMX) is a publicly traded Healthcare sector company. As of May 21, 2026, CTMX trades at $3.74 with a market cap of $761.96M and a P/E ratio of 0.00. CTMX moved +2.06% today. Year to date, CTMX is -9.71%; over the trailing twelve months it is +80.58%. Its 52-week range spans $0.40 to $8.21. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces CTMX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CytomX Raises $250M, Holds $346.7M Cash; Varseta-M Dose Expansion Completes Enrollment: CytomX ended Q1 2026 with $346.7M in cash and investments following a $250M equity offering, funding operations into H2 2028. The company completed enrollment of 40 patients in Varseta-M Phase 1 dose optimization (8.6 and 10 mg/kg Q3W), with data expected in 2H 2026 to guide registrational plans.
| Metric | Value |
|---|---|
| Price | $3.74 |
| Market Cap | $761.96M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.21 |
| 52-Week Low | $0.40 |
| Volume | 749 |
| Avg Volume | 0 |
| Revenue (TTM) | $35.54M |
| Net Income | $-59.14M |
| Gross Margin | 0.00% |
9 analysts cover CTMX: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.